Lista de obras -

A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY

artículo científico publicado en 2020

A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1

artículo científico publicado en 2018

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

artículo científico publicado en 2020

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

artículo científico publicado en 2019

Advances in POEMS treatment and the need to define standardised outcome measures

artículo científico publicado en 2018

An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma

artículo científico publicado en 2014

Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation

artículo científico publicado en 2003

Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI.

artículo científico publicado en 2013

Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al.

artículo científico publicado en 2014

Bortezomib-induced inflammatory neuropathy.

artículo científico publicado en 2010

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

artículo científico publicado en 2015

Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study

artículo científico publicado en 2020

Cold agglutinin disease revisited: A multinational, observational study of 232 patients

scientific article published on 06 May 2020

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

scientific article published on 30 July 2020

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

artículo científico publicado en 2020

Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

artículo científico publicado en 2005

Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy

scientific article published on 11 July 2020

Diffusion‐weighted MRI compared to FDG PET‐CT in the staging and response assessment of Hodgkin lymphoma ⬇️

artículo científico publicado el 8 de diciembre de 2011

Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs

scientific article published on 26 October 2020

Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincr

artículo científico publicado en 2012

Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects

artículo científico publicado en 2004

Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome

article

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

artículo científico publicado en 2016

Guidelines for supportive care in multiple myeloma 2011.

scientific article published on 22 April 2011

Guidelines for the diagnosis and management of multiple myeloma 2011 ⬇️

artículo científico publicado el 14 de mayo de 2011

Guidelines for the use of imaging in the management of myeloma.

artículo científico publicado en 2007

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

artículo científico publicado en 2014

High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.

artículo científico publicado en 2017

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry

artículo científico publicado en 2020

High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise?

artículo científico publicado en 2019

IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness

scientific article published on 06 October 2019

Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma

artículo científico publicado en 2012

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

scientific article published on 17 December 2018

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program

artículo científico publicado en 2020

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel

artículo científico publicado en 2017

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2005

Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.

artículo científico publicado en 2018

POEMS neuropathy: optimising diagnosis and management.

artículo científico publicado en 2018

Peripheral nerve neurolymphomatosis: clinical features, treatment and outcomes

artículo científico publicado en 2020

Prevalence and Course of Endocrinopathy in POEMS Syndrome

scientific article published on 01 June 2019

Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome

article published in 2018

Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse

artículo científico publicado en 2016

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

artículo científico publicado en 2017

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

scientific article published on 01 April 2003

Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia

scientific article published on 02 September 2011

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

artículo científico publicado en 2016

T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated don

artículo científico publicado en 2003

Therapie einer Lymphknotentuberkulose

artículo científico publicado en 2010

Treatment for lymph node tuberculosis

scientific article published in the British Medical Journal

Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy

artículo científico publicado en 2015

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

artículo científico publicado en 2009

Untangling a case of painful neuropathy

scientific article published on 04 October 2019

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma

artículo científico publicado en 2013

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

scientific article published on 21 October 2016

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction

artículo científico publicado en 2017

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

artículo científico publicado en 2020

[18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia.

artículo científico publicado en 2018

Lista de obras de

A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY

A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Advances in POEMS treatment and the need to define standardised outcome measures

An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma

Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation

Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI.

Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al.

Bortezomib-induced inflammatory neuropathy.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study

Cold agglutinin disease revisited: A multinational, observational study of 232 patients

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy

Diffusion‐weighted MRI compared to FDG PET‐CT in the staging and response assessment of Hodgkin lymphoma ⬇️

Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs

Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincr

Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects

Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

Guidelines for supportive care in multiple myeloma 2011.

Guidelines for the diagnosis and management of multiple myeloma 2011 ⬇️

Guidelines for the use of imaging in the management of myeloma.

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry

High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise?

IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness

Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.

POEMS neuropathy: optimising diagnosis and management.

Peripheral nerve neurolymphomatosis: clinical features, treatment and outcomes

Prevalence and Course of Endocrinopathy in POEMS Syndrome

Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome

Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated don

Therapie einer Lymphknotentuberkulose

Treatment for lymph node tuberculosis

Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

Untangling a case of painful neuropathy

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

[18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia.